SANUWAVE Health Partners with The Mobile Health Company, a New Company Formed by Former President Shri Parikh

SUWANEE, GA, May 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce they will be offering dermaPACE System solutions to treat patients in a home setting.  SANUWAVE Health will also have devices placed with THE MOBILE HEALTH COMPANY (MHC), a business recently formed by former SANUWAVE President Shri Parikh.

SANUWAVE Health has quickly adapted to the changes occurring in the world of wound care.  Following on the announcement last week of 10 sites using dermaPACE mobile, SANUWAVE Health is pleased to announce they are partnering with former President Shri Parikh, who is launching a mobile solution to wound care and other treatments directly to the patient’s home setting. In doing so, Shri will be resigning from SANUWAVE as President, however, he remains an active company advisor.  Shri comments, “I’m very excited about this collaboration with SANUWAVE. What THE MOBILE HEALTH COMPANY offers is particularly valuable now, a time where patients are fearful and limited to getting essential care they need. In Wound Care, amputation is an almost certain outcome for DFU patients that go untreated. With MHC, we can offer continuous care, in a safe and clean environment, with state of the art technologies, such as dermaPACE, to reduce the systems’ chronic care costs burden, while improving patient compliance and outcomes.” SANUWAVE CEO Kevin Richardson added, “We are excited to partner with Shri and his new business model. I am confident MHC will be an extremely successful venture which SANUWAVE can grow with as MHC enters new regions around the country.”

About SANUWAVE Health, Inc. 

SANUWAVE Health, Inc. (OTCQB: SNWV) is a shockwave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE, is US FDA cleared for the treatment of Diabetic Foot Ulcers.  The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia, and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron and orthoPACE devices in Europe, Asia, and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shockwave technology for non-medical uses, including energy, water, food, and industrial markets.